HLB liver cancer drug hits FDA setback again over manufacturing issues
HLB's hopes of bringing its liver cancer treatment to the US market have suffered another blow after the US Food and Drug Administration issued a Complete Response Letter delaying approval, citing…
Read the full articleYou might also wanna read
HLB Shares Plunge to Daily Limit After FDA Rejects Liver Cancer Drug
HLB shares plunged nearly 30% to their daily limit on the 10th after the U.S. FDA issued a third Complete Response Letter for its liver canc
HLB Shares Hit Daily Limit-Down on FDA Response Letter for Liver Cancer Drug
HLB shares hit daily limit-down after its liver cancer drug rivoceranib received a Complete Response Letter from the FDA, citing cGMP inspec
A Study of Combination Therapy in Patients With Resectable Liver Cancer
Conditions : Liver Cancer (Primary and Metastatic) Interventions : Drug: Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Pl
HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Conditions : Liver Cancer Interventions : Device: DEB-TACE; Drug: Toripalimab; Drug: Lenvatinib; Drug: Gemcitabine; Drug: Oxaliplatin Sponso
A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
Conditions : Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk Interventions : Drug: SHR-8068 Injection; Drug: A
FDA-approved drug may finally help immunotherapy defeat rare liver cancer
Researchers found that a rare liver cancer evades immunotherapy by luring immune T cells away from the tumor and trapping them in nearby fib
Comments
Sign in to join the conversation.
No comments yet. Be the first.